Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRD9 | Q9H8M2 | 4/20 | 0.47 |
| ▸ | BRD4 | O60885 | 17/20 | 0.46 |
| ▸ | GABBR2 | O75899 | 1/20 | 0.42 |
| ▸ | BRD2 | P25440 | 1/20 | 0.42 |
| ▸ | EP300 | Q09472 | 1/20 | 0.42 |
| ▸ | BRD3 | Q15059 | 1/20 | 0.42 |
| ▸ | BRDT | Q58F21 | 1/20 | 0.42 |
| ▸ | PBRM1 | Q86U86 | 1/20 | 0.42 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.42 |
| ▸ | KAT2A | Q92830 | 1/20 | 0.42 |
| ▸ | BRD7 | Q9NPI1 | 1/20 | 0.42 |
| ▸ | GABBR1 | Q9UBS5 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30811949 | 0.90 | BRD4 (0.48) | BRD9BRD4 | |
| SCHEMBL30812098 | 0.85 | BRD4 (0.46) | BRD9BRD4 | |
| SCHEMBL30812073 | 0.84 | BRD4 (0.52) | BRD9BRD4 | |
| SCHEMBL30812183 | 0.83 | BRD4 (0.51) | BRD9BRD4 | |
| SCHEMBL30812297 | 0.81 | BRD9 (0.48) | BRD9BRD4 | |
| SCHEMBL30812225 | 0.78 | BRD4 (0.52) | BRD9BRD4 | |
| SCHEMBL31245965 | 0.77 | BRD4 (0.48) | BRD9BRD4 | |
| SCHEMBL30812199 | 0.76 | BRD4 (0.48) | BRD9BRD4 | |
| SCHEMBL30824784 | 0.76 | BRD4 (0.51) | BRD9BRD4 | |
| SCHEMBL27391659 | 0.76 | BRD4 (0.51) | BRD9BRD4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024054956-A1 | HETEROBIFUNCTIONAL COMPOUNDS AND METHODS OF TREATING DISEASE | HALDA THERAPEUTICS OPCO, INC. (US) | 2024-03-14 | — | — | WO | disclosed |